Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02494700
Other study ID # 2014-1046
Secondary ID NCI-2015-0120320
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date July 6, 2015
Est. completion date June 30, 2025

Study information

Verified date May 2024
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies how well ultra low dose orbital radiation therapy works in treating patients with stage I-IV low grade (indolent) B-cell lymphoma or mantle cell lymphoma involving the orbit of the eye (space enclosed by the borders of the eye socket). Orbital radiation therapy uses external beam radiation to destroy cancer cells. Using ultra low dose orbital radiation therapy may be effective in treating indolent B-cell lymphoma or mantle cell lymphoma involving the eye and may have fewer side effects.


Description:

PRIMARY OBJECTIVES: I. To evaluate the efficacy of ultra low dose 4 Gray (Gy) orbital radiation, measured as local orbital control (i.e. local control within the radiation field), in patients with limited and advanced stage low grade B lymphocyte (B cell) lymphoma and mantle cell lymphoma involving the ocular adnexa. II. To evaluate the efficacy of ultra low dose 4 Gy orbital radiation, measured as complete response, in patients with limited and advanced stage low grade B cell lymphoma and mantle cell lymphoma involving the ocular adnexa. III. To evaluate the acute and chronic toxicity of radiation to the orbit. SECONDARY OBJECTIVE: I. To determine if dynamic contrast enhanced magnetic resonance imaging can predict response to ultra low dose radiation therapy. OUTLINE: Patients undergo low dose orbital external beam radiation therapy (EBRT) on 2 consecutive days. Patients experiencing stable or progressive disease after 12-16 weeks of EBRT undergo additional low dose orbital EBRT over 10 fractions. Patients experiencing partial response or minimal response 1 year after EBRT also undergo low dose orbital EBRT over 10 fractions. After completion of study treatment, patients are followed up every 3-4 months for 6-8 months, every 6-12 months for up to 2 years, and then periodically thereafter.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date June 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients 18 years or older with stage I-IV indolent B cell lymphoma, including MALT and follicular grade I/II. Patients with mantle cell lymphoma will also be included in this study, as mantle cell lymphoma is also radiosensitive, despite it not being an indolent B cell lymphoma. Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) are ineligible. - Patients must have measurable disease within the orbit, either clinically and/or radiographically after biopsy confirmation of B cell lymphoma. - Bilateral ocular adnexal involvement is permitted, if biopsy confirms unilateral disease and there is high clinical suspicion for bilateral disease, biopsy of the contralateral ocular adnexa can be waived. - Female patients of childbearing potential must have a negative serum pregnancy test (ßhCG) within 2 weeks of protocol entry. - Planned systemic therapy after orbital radiation therapy is permitted however the timing of systemic therapy will be recorded and patients will be stratified according to receipt of adjuvant systemic therapy. - Male patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the study. - Female patients must be willing to use two adequate barrier methods of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study or be post-menopausal (free from menses > two years or surgically sterilized). - Patients must have the ability to give informed consent. Exclusion Criteria: - Patients treated with chemotherapy for lymphoma within 4 weeks of protocol enrollment (including Rituxan). - Patients with aggressive B cell lymphoma histology, including diffuse large B cell lymphoma (DLBCL) and grade 3 follicular lymphoma. - Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). - Patients with a history of prior radiation to the orbit if re-treatment would exceed known orbital tolerance. - Patients with pre-existing retinopathy. - Patients who are pregnant. - Patients with active lupus or scleroderma are ineligible

Study Design


Related Conditions & MeSH terms

  • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
  • Ann Arbor Stage I Grade 1 Follicular Lymphoma
  • Ann Arbor Stage I Grade 2 Follicular Lymphoma
  • Ann Arbor Stage I Indolent Adult Non-Hodgkin Lymphoma
  • Ann Arbor Stage I Mantle Cell Lymphoma
  • Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma
  • Ann Arbor Stage II Grade 1 Follicular Lymphoma
  • Ann Arbor Stage II Grade 2 Follicular Lymphoma
  • Ann Arbor Stage II Indolent Adult Non-Hodgkin Lymphoma
  • Ann Arbor Stage II Mantle Cell Lymphoma
  • Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma
  • Ann Arbor Stage III Grade 1 Follicular Lymphoma
  • Ann Arbor Stage III Grade 2 Follicular Lymphoma
  • Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma
  • Ann Arbor Stage III Mantle Cell Lymphoma
  • Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
  • Ann Arbor Stage IV Grade 1 Follicular Lymphoma
  • Ann Arbor Stage IV Grade 2 Follicular Lymphoma
  • Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma
  • Ann Arbor Stage IV Mantle Cell Lymphoma
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, B-Cell, Marginal Zone
  • Lymphoma, Follicular
  • Lymphoma, Mantle-Cell
  • Lymphoma, Non-Hodgkin
  • Ocular Adnexal Lymphoma
  • Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
  • Orbit Lymphoma

Intervention

Radiation:
External Beam Radiation Therapy
Undergo orbital EBRT
Drug:
Orbital Radiation
Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Local orbital control (i.e. local control within the radiation field) Local orbital event will be estimated using the Kaplan-Meier method. Up to 2 years post-radiation
Secondary Complete response rate Response rate will be estimated along with 95% confidence intervals. Up to 2 years
Secondary Local regional control (i.e. local control within the ipsilateral orbit but outside of the radiation field) Up to 2 years post-radiation therapy
Secondary Overall survival (OS) OS will be estimated using the Kaplan-Meier method. Up to 2 years
Secondary Freedom from distant relapse rates Up to 2 years
Secondary Incidence of acute and chronic ocular toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 Toxicity data will be summarized by frequency tables. Up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05025800 - ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Active, not recruiting NCT01829568 - Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma Phase 1
Completed NCT01145495 - Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma Phase 2
Completed NCT00695786 - Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma Phase 2
Active, not recruiting NCT04404088 - Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma Phase 2
Completed NCT02320292 - Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma Phase 3
Active, not recruiting NCT02871219 - Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma Phase 2
Active, not recruiting NCT01286272 - Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Phase 2